Agreement reached with FDA on Phase 2 pivotal study design of RP-L301 for PKD to support accelerated approval; Initiating single-arm, 10-patient pivotal study with primary endpoint of ≥1.5 point Hgb improvement at 12 monthsInitiated Phase 2 pivotal trial of RP-A501 for Danon Disease following FDA alignmentInitiated.